Carcinogenesis, Vol. 22, No. 7, 1061-1067,
July 2001
© 2001 Oxford University Press
CANCER BIOLOGY |
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2
Second Department of Medicine, J.W.Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
Mevastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis. Butyrate, a short-chain fatty acid, reduces proliferation and induces differentiation of human colon cancer cells. The aim of our study was to determine the effect of mevastatin, alone or in combination with butyrate, on proliferation, the cell cycle and apoptosis in the human colorectal carcinoma cell line Caco-2. In this report we show that mevastatin combined with butyrate synergistically suppressed growth of Caco-2 cells in a dose- and time-dependent manner. In addition, incubation with mevastatin arrested cells in the G1 phase of the cell cycle after 24 h with a switch to the G2/M phase after 72 h. This was accompanied by a down-regulation of cyclin-dependent kinases (cdk) 4 and cdk 6 as well as cyclin D1, while cdk 2 and cyclin E protein levels remained unchanged during mevastatin treatment. Cell cycle inhibitors p21 and p27 were significantly upregulated by mevastatin. The proapoptotic properties of mevastatin were further enhanced by co-incubation with butyrate. Lastly, the effects of mevastatin could be reversed by addition of mevalonate, but not farnesyl- or geranylgeranylpyrophosphate, intermediate products of cholesterol synthesis, to the medium. These results suggest that HMG-CoA reductase inhibitors like mevastatin may enhance the antiproliferative effect of butyrate in colon cancer cells via induction of apoptosis together with a G0/G1 cell cycle arrest.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Lu, H. Xiao, H. You, Y. Lin, H. Jin, B. Snagaski, and C. S. Yang Synergistic Inhibition of Lung Tumorigenesis by a Combination of Green Tea Polyphenols and Atorvastatin Clin. Cancer Res., August 1, 2008; 14(15): 4981 - 4988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Reddy, C. X. Wang, A.-N. Kong, T. O. Khor, X. Zheng, V. E. Steele, L. Kopelovich, and C. V. Rao Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in f 344 rats. Cancer Res., April 15, 2006; 66(8): 4542 - 4546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Zambell, M. D. Fitch, and S. E. Fleming Acetate and Butyrate Are the Major Substrates for De Novo Lipogenesis in Rat Colonic Epithelial Cells J. Nutr., November 1, 2003; 133(11): 3509 - 3515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Y. Wang, W.-B. Zhong, T.-C. Chang, S.-M. Lai, and Y.-F. Tsai Lovastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, Induces Apoptosis and Differentiation in Human Anaplastic Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3021 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Fouty and D. M. Rodman Mevastatin Can Cause G1 Arrest and Induce Apoptosis in Pulmonary Artery Smooth Muscle Cells Through a p27Kip1-Independent Pathway Circ. Res., March 21, 2003; 92(5): 501 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. W. Chan, A. M. Oza, and L. L. Siu The Statins as Anticancer Agents Clin. Cancer Res., January 1, 2003; 9(1): 10 - 19. [Abstract] [Full Text] [PDF]
|
|